Drugs / TYK-01054
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07282873 | Jan 2026 → Jan 2028 expected | malignant mesothelioma | TYK Medicines, Inc | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYK-01054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07282873 ↗ |
| Action | Inhibit | “the TEAD inhibitor TYK-01054 capsules” NCT07282873 ↗ |